BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, Thomas DL, Mehta SH. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int 2020;40:2407-16. [PMID: 32770638 DOI: 10.1111/liv.14634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. J Int AIDS Soc 2018;21 Suppl 2:e25051. [PMID: 29633559 DOI: 10.1002/jia2.25051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
3 Rizk C, Miceli J, Shiferaw B, Malinis M, Barakat L, Ogbuagu O, Villanueva M. Implementing a Comprehensive HCV Clinic within an HIV Clinic: A Model of Care for HCV Micro-elimination. Open Forum Infect Dis. 2019;Online ahead of print. [PMID: 31412130 DOI: 10.1093/ofid/ofz361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Rivero‐juarez A, Tellez F, Castaño‐carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua‐garcía M, Zapata‐lopez A, Collado A, Gómez‐vidal M, Perez‐stachowski J, Muñoz‐medina L, Fernandez‐fuertes E, Rivero A; on behalf of the Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV ‐infected patients. HIV Med 2019. [DOI: 10.1111/hiv.12715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
6 Gicquelais RE, Foxman B, Coyle J, Eisenberg MC. Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics 2019;27:86-95. [PMID: 30930214 DOI: 10.1016/j.epidem.2019.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ortiz-paredes D, Amoako A, Lessard D, Engler K, Lebouché B, Klein MB. Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers. CanLivJ 2022;5:14-30. [DOI: 10.3138/canlivj-2021-0021] [Reference Citation Analysis]
8 Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection Cohort Study Investigators. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis 2020;71:363-71. [PMID: 31504327 DOI: 10.1093/cid/ciz833] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Juanbeltz R, Pérez-García A, Aguinaga A, Martínez-Baz I, Casado I, Burgui C, Goñi-Esarte S, Repáraz J, Zozaya JM, San Miguel R, Ezpeleta C, Castilla J; EIPT-VHC Study Group. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One 2018;13:e0208554. [PMID: 30513107 DOI: 10.1371/journal.pone.0208554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
10 Socías ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K, Debeck K, Milloy MJ. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int 2019;39:1400-7. [PMID: 30653809 DOI: 10.1111/liv.14043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
11 Pearce ME, Jongbloed K, Demerais L, MacDonald H, Christian WM, Sharma R, Pick N, Yoshida EM, Spittal PM, Klein MB. "Another thing to live for": Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. Int J Drug Policy 2019;74:52-61. [PMID: 31525640 DOI: 10.1016/j.drugpo.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
12 Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy 2020;86:102964. [DOI: 10.1016/j.drugpo.2020.102964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kronfli N, Nitulescu R, Cox J, Moodie EE, Wong A, Cooper C, Gill J, Walmsley S, Martel-Laferrière V, Hull MW, Klein MB; Canadian Co-Infection Cohort Study. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. J Int AIDS Soc 2018;21:e25197. [PMID: 30460791 DOI: 10.1002/jia2.25197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
14 Driedger M, Vachon M, Wong A, Conway B, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld J, Lee SS, Cooper C. Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. CanLivJ 2021;4:283-91. [DOI: 10.3138/canlivj-2021-0003] [Reference Citation Analysis]
15 Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. CanLivJ 2018;1:231-9. [DOI: 10.3138/canlivj.2018-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferrière V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. AIDS 2019;33:1013-22. [PMID: 30946155 DOI: 10.1097/QAD.0000000000002156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
17 Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health 2021;20:81. [PMID: 33740984 DOI: 10.1186/s12939-021-01420-7] [Reference Citation Analysis]
18 Falade-Nwulia O, Sacamano P, McCormick SD, Yang C, Kirk G, Thomas D, Sulkowski M, Latkin C, Mehta SH. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Int J Drug Policy 2020;78:102714. [PMID: 32135398 DOI: 10.1016/j.drugpo.2020.102714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Int J Drug Policy 2022;103:103627. [PMID: 35218989 DOI: 10.1016/j.drugpo.2022.103627] [Reference Citation Analysis]
20 Yanes-Lane M, Dussault C, Linthwaite B, Cox J, Klein MB, Sebastiani G, Lebouché B, Kronfli N. Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. J Viral Hepat 2020;27:205-20. [PMID: 31638294 DOI: 10.1111/jvh.13220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Marathe G, Moodie EEM, Brouillette M, Cox J, Delaunay CL, Cooper C, Hull M, Gill J, Walmsley S, Pick N, Klein MB; Canadian Co-Infection Cohort. Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada. Antiviral Therapy 2022;27:135965352110676. [DOI: 10.1177/13596535211067610] [Reference Citation Analysis]
22 Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PLoS One 2019;14:e0218759. [PMID: 31437170 DOI: 10.1371/journal.pone.0218759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Lau AA, Strebe JK, Sura TV, Hansen LA, Jain MK. Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.645] [Reference Citation Analysis]
24 van Boemmel-Wegmann S, Lo Re V 3rd, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020;65:3159-74. [PMID: 31938995 DOI: 10.1007/s10620-019-06037-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Rojas Rojas T, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B, Marcellin F. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. Int J Drug Policy 2019;72:61-8. [PMID: 31129024 DOI: 10.1016/j.drugpo.2019.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS One 2018;13:e0199874. [PMID: 29975764 DOI: 10.1371/journal.pone.0199874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int 2019;39:2244-60. [PMID: 31125496 DOI: 10.1111/liv.14152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
28 Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat 2019;100:45-51. [PMID: 30898327 DOI: 10.1016/j.jsat.2019.01.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
29 Greenaway C, Makarenko I, Tanveer F, Janjua NZ. Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada. CanLivJ 2018;1:34-50. [DOI: 10.3138/canlivj.1.2.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
30 Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 2020;3:e204192. [PMID: 32374397 DOI: 10.1001/jamanetworkopen.2020.4192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ortiz-paredes D, Amoako A, Lessard D, Engler K, Lebouché B, Klein MB. Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patients and treatment provider perceptions. CanLivJ. [DOI: 10.3138/canlivj-2021-0020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB; Canadian Co-Infection Cohort Study. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy 2019;65:41-9. [PMID: 30594080 DOI: 10.1016/j.drugpo.2018.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME. Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment? Expert Rev Anti Infect Ther 2018;16:411-22. [PMID: 29722275 DOI: 10.1080/14787210.2018.1471355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Lanièce Delaunay C, Godin A, Kronfli N, Panagiotoglou D, Cox J, Alary M, Klein MB, Maheu-Giroux M. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? Int J Drug Policy 2021;:103343. [PMID: 34215459 DOI: 10.1016/j.drugpo.2021.103343] [Reference Citation Analysis]
35 Pearce ME, Jongbloed K, Pooyak S, Christian WM, Teegee MGWWM, Caron NR, Thomas V, Henderson E, Zamar D, Yoshida EM, Schechter MT, Spittal PM. The Cedar Project: exploring the role of colonial harms and childhood maltreatment on HIV and hepatitis C infection in a cohort study involving young Indigenous people who use drugs in two Canadian cities. BMJ Open 2021;11:e042545. [PMID: 34244246 DOI: 10.1136/bmjopen-2020-042545] [Reference Citation Analysis]
36 Tran L, Feldman R, Riley T 3rd, Jung J. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C. JAMA Netw Open 2021;4:e2115523. [PMID: 34213557 DOI: 10.1001/jamanetworkopen.2021.15523] [Reference Citation Analysis]
37 Ortiz-paredes D, Amoako A, Ekmekjian T, Engler K, Lebouché B, Klein MB. Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. Front Public Health 2022;10:877585. [DOI: 10.3389/fpubh.2022.877585] [Reference Citation Analysis]
38 Marshall AD, Rance J, Grebely J, Treloar C. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy 2022;102:103610. [PMID: 35151085 DOI: 10.1016/j.drugpo.2022.103610] [Reference Citation Analysis]